Abstract
Stem cell transplantation is increasingly used in the management of immunoglobulin light-chain amyloidosis (AL). It is considered the standard of care to administer growth factors to accelerate neutrophil recovery after transplantation. However, unique toxicities occur with growth factor use in patients with AL who receive a stem cell transplant. We report a cohort of patients who underwent transplantation without receiving posttransplantation growth factors. In total, 282 patients received a stem cell transplant. A neutrophil count of 500/μl was achieved in 50, 75 and 90% of patients at 14, 16 and 22 days, respectively. A platelet count of 20 000/μl was achieved in 50, 75 and 90% of patients at 14, 20 and 31 days, respectively. Non-staphylococcal bacteremia was detected in 16% of patients. The median hospital stay was 9 days. It is feasible and reasonable to withhold growth factor therapy after autologous stem cell transplantation in patients with AL.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Jansen J, Hanks S, Thompson JM, Dugan MJ, Akard LP . Transplantation of hematopoietic stem cells from the peripheral blood. J Cell Mol Med 2005; 9: 37–50.
Gabrilove JL . An analysis of current neutropenia therapies, including pegfilgrastim. Clin Cornerstone 2006; 8 (Suppl 5): S19–S28.
Akard LP, Thompson JM, Dugan MJ, Wiemann M, Greenspan A, Hanks S et al. Matched-pair analysis of hematopoietic progenitor cell mobilization using G-CSF vs. cyclophosphamide, etoposide, and G-CSF: enhanced CD34 cell collections are not necessarily cost-effective. Biol Blood Marrow Transplant 1999; 5: 379–385.
Worel N, Schulenburg A, Mitterbauer M, Keil F, Rabitsch W, Kalhs P et al. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity. Wien Klin Wochenschr 2006; 118: 49–53.
Perotti C, Del Fante C, Viarengo G, Perlini S, Vezzoli M, Rodi G et al. Peripheral blood progenitor cell mobilization and collection in 42 patients with primary systemic amyloidosis. Transfusion 2005; 45: 1729–1734.
Leung N, Leung TR, Cha SS, Dispenzieri A, Lacy MQ, Gertz MA . Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients. Blood 2005; 106: 3353–3357; e-pub ahead of print 21 July 2005.
Dember LM, Sanchorawala V, Seldin DC, Wright DG, LaValley M, Berk JL et al. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on AL amyloidosis-associated renal disease. Ann Intern Med 2001; 134: 746–753.
Oran B, Wright DG, Seldin DC, McAneny D, Skinner M, Sanchorawala V . Spontaneous rupture of the spleen in AL amyloidosis. Am J Hematol 2003; 74: 131–135.
Sanchorawala V, Wright DG, Seldin DC, Falk RH, Finn KT, Dember LM et al. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplant 2004; 33: 381–388.
Sanchorawala V, Wright DG, Seldin DC, Dember LM, Finn K, Falk RH et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 2001; 28: 637–642.
Burgstaler EA, Pineda AA, Winters JL . Hematopoietic progenitor cell large volume leukapheresis (LVL) on the Fenwal Amicus blood separator. J Clin Apher 2004; 19: 103–111.
Balducci L, Carreca I . The role of myelopoietic growth factors in managing cancer in the elderly. Drugs 2002; 62 (Suppl 1): 47–63.
Crawford J . Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy. Pharmacotherapy 2003; 23: 15S–19S.
Oran B, Malek K, Sanchorawala V, Wright DG, Quillen K, Finn KT et al. Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis. Bone Marrow Transplant 2005; 35: 567–575 [Erratum in: Bone Marrow Transplant 2005; 35: 635].
Tarella C, Castellino C, Locatelli F, Caracciolo D, Corradini P, Falda M et al. G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs. Bone Marrow Transplant 1998; 21: 401–407.
Klaus J, Herrmann D, Breitkreutz I, Hegenbart U, Mazitschek U, Egerer G et al. Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Eur J Haematol 2007; 78: 21–28.
Ketterer N, Espinouse D, Chomarat M, Dumontet C, Moullet I, Rieux C et al. Infections following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: etiology and potential risk factors. Am J Med 1999; 106: 191–197.
Reich G, Mapara MY, Reichardt P, Dorken B, Maschmeyer G . Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors. Bone Marrow Transplant 2001; 27: 525–529.
Kolbe K, Domkin D, Derigs HG, Bhakdi S, Huber C, Aulitzky WE . Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation. Bone Marrow Transplant 1997; 19: 143–147.
Moreau P, Leblond V, Bourquelot P, Facon T, Huynh A, Caillot D et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol 1998; 101: 766–769.
Perz JB, Schonland SO, Hundemer M, Kristen AV, Dengler TJ, Zeier M et al. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study. Br J Haematol 2004; 127: 543–551.
Ojeda E, Garcia-Bustos J, Agaudo MJ, Quevedo E, Arrieta R, Jimenez V et al. Is filgrastim as useless after peripheral blood stem cell transplantation for adults as it could be for children? Blood 1999; 93: 3565–3566.
Bird JM, Fuge R, Sirohi B, Apperley JF, Hunter A, Snowden J, et al, British Society of Blood and Marrow Transplantation. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study. Br J Haematol 2006; 134: 385–390; e-pub ahead of print 5 July 2006.
Acknowledgements
Editing, proofreading and reference verification were provided by the Section of Scientific Publications, Mayo Clinic.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gertz, M., Lacy, M., Dispenzieri, A. et al. Transplantation without growth factor: engraftment kinetics after stem cell transplantation for primary systemic amyloidosis (AL). Bone Marrow Transplant 40, 989–993 (2007). https://doi.org/10.1038/sj.bmt.1705848
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705848
Keywords
This article is cited by
-
Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis
Bone Marrow Transplantation (2012)
-
SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization
Bone Marrow Transplantation (2011)
-
Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma
Bone Marrow Transplantation (2009)